Rockland Immunochemicals now offers immunoassay development and bioanalytical services utilizing our expertise in producing antibodies (in vitro and in vivo) to various targets which monitor important signaling events. Rockland's DualLISA™ assay technology optimizes polyclonal and monoclonal antibodies produced for more highly sensitive and quantitative assays than standard ELISAs, saving time during the intensive screening process. Furthermore the advantages of DualLISA™ allow for the rapid development of reagents which can be incorporated onto High Content Screening Platforms. Successful targets to date have been AKT, Pdcd4 and STAT5.
To further enable innovative biomarker development for drug discovery and diagnostics applications, Rockland Immunochemicals offers highly customized solutions to meet your basic, applied, and clinical research demands. Whether its the generation of highly specific antibodies or the development of unique in vitro assay systems, Rockland Immunochemicals provides the scientific expertise and cGMP compliant manufacturing facilities necessary to support your biomarker evaluation and development needs, globally.
For over 40 years, Rockland Immunochemicals has supported the life science industry with a full range of the highest quality primary and secondary antibodies, fusion proteins, substrates, standards, and controls for basic research, assay development, and preclinical studies.